Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Johnson & Johnson Opens Bay Area Biotech Incubator

Published 03/03/2015, 02:15 PM
Updated 03/03/2015, 02:45 PM
© Wikimedia Commons. Johnson and Johnson opened a new biotech incubator in South San Francisco which will host 10 companies working to develop medical devices and pharmaceuticals in a 'no strings attached' arrangement. Johnson and Johnson already operates three incubators in other cities and has made over a dozen deals with their members.

© Wikimedia Commons. Johnson and Johnson opened a new biotech incubator in South San Francisco which will host 10 companies working to develop medical devices and pharmaceuticals in a 'no strings attached' arrangement. Johnson and Johnson already operates three incubators in other cities and has made over a dozen deals with their members.

By Amy Nordrum -

© Wikimedia Commons. Johnson and Johnson opened a new biotech incubator in South San Francisco which will host 10 companies working to develop medical devices and pharmaceuticals in a 'no strings attached' arrangement. Johnson and Johnson already operates three incubators in other cities and has made over a dozen deals with their members.

Johnson & Johnson (NYSE:JNJ) announced the grand opening of a biotech incubator in South San Francisco on Tuesday and unveiled the first 10 businesses that will reside there. The 30,000-square foot facility can house up to 50 startups at a time, and its members will focus on developing healthcare solutions in the highly competitive industries of pharmaceuticals, medical devices and digital health.

The inaugural members of the incubator, called a JLab, will include start-ups focused on chronic pain, rare diseases and skin cancer. Employees of a firm called Goleini Inc. who are developing a gene therapy for glaucoma will work there along with the team at Corexyme, which is trying to stave off Alzheimer’s disease.

"You've got young scientists with first-time startups, but we also decided to have some seriously experienced serial founders and heavyweights come in, so that we have this great mix of dynamic new talent and experienced wisdom," Melinda Richter, head of the innovation for Johnson & Johnson, told FierceBiotech. "And that's really what the community is about."

One member company called Applied Molecular Transport has already announced a partnership with Janssen Biotech Inc., a division of Johnson & Johnson, for a treatment of inflammatory bowel disease. Another called EpiBiome Inc. earned its place in the incubator by winning a competition hosted earlier this year and is attempting to treat diseases in livestock by tapping the microbiome, the term for the many microorganisms that reside within humans and other large animals.

California is already home to 2,490 companies that focus on biomedicine, which is more than any other state. Its lawmakers have offered startup-friendly policies including a sales tax exemption for companies to use when purchasing equipment related to research and development. Even during the recession, which hit California particularly hard, this homegrown industry continued to grow at a faster clip than in any state except North Carolina, according to a report by PricewaterhouseCoopers. "The addition of JLabs to the Bay Area is a welcome and needed resource that will help advance innovative products and further support the formation of additional life science companies," Richard Garbarino, mayor of South San Francisco, said in a statement.

Johnson & Johnson runs similar incubators in San Francisco, San Diego and Boston and plans to open a fifth in Houston next year. Members of each incubator rent space and gain access to laboratory equipment, business services, educational programs and offices as part of a “no strings attached” arrangement, according to the company’s website. However, it's clear that Johnson and Johnson sees the 70 companies housed in its JLabs throughout the country as a loosely held extension of the company's own innovation arm. Over the years, Johnson and Johnson has struck 20 deals with member companies for products or medicines created at its incubators and is currently in negotiations for 20 more, as reported by San Francisco Business Times.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.